Obstructive Sleep Apnea (OSA) Annual Evaluation Checklist

Why an Annual OSA Evaluation Matters

OSA is not a set-and-forget diagnosis. Approximately 936 million adults worldwide carry the condition, yet adherence to positive-airway-pressure therapy drops below the 70% threshold in a substantial portion of patients within the first year of treatment. [1] The American Academy of Sleep Medicine (AASM) 2023 clinical practice guidelines state that "clinicians should perform periodic reassessment of patients with OSA to evaluate treatment effectiveness, adherence, and the development of comorbidities." [2] A missed annual review means missed opportunities to catch worsening AHI, new-onset hypertension, or changing body weight that could alter treatment intensity.

The Stakes of Undertreated OSA

Untreated moderate-to-severe OSA roughly doubles the long-term risk of systemic hypertension. [3] The Wisconsin Sleep Cohort, which tracked over 1,500 participants for up to 18 years, found that an AHI ≥15 at baseline was associated with a 3-fold increase in all-cause mortality compared with an AHI <5. [4] Those numbers make the annual check-in a genuine safety net, not a billing formality.

Regulatory and Medicolegal Context

Commercial drivers holding a Federal Motor Carrier Safety Administration (FMCSA) certificate must demonstrate adequate OSA treatment to maintain certification. Clinicians who skip the annual documentation review expose both the patient and themselves to liability. The FMCSA medical examiner handbook explicitly lists OSA as a potentially disqualifying condition unless adequately treated and documented. [5]

Step 1: Review Diagnostic Criteria and Re-Establish Baseline

Before updating a care plan, confirm the original diagnosis meets current AASM criteria. OSA requires either AHI ≥5 events/hour with at least one symptom (witnessed apneas, snoring, sleepiness, or awakening with gasping) or AHI ≥15 events/hour regardless of symptoms, documented on a qualifying polysomnogram (PSG) or home sleep apnea test (HSAT). [2]

Was the Original Study Adequate?

HSAT can underestimate AHI by 10-20% relative to PSG in some patients because it lacks cortical arousal scoring. If the patient was originally tested with HSAT and treatment response has been poor, ordering a full in-lab PSG may be warranted. A 2021 Cochrane review of 13 trials confirmed that HSAT is adequate for uncomplicated suspected OSA but performs less reliably in patients with heart failure, chronic obstructive pulmonary disease, or suspected central sleep apnea. [6]

AHI Severity Tiers

• Mild: AHI 5-14.9 events/hour
• Moderate: AHI 15-29.9 events/hour
• Severe: AHI ≥30 events/hour

Document the original severity tier in the annual note so any trajectory changes are immediately visible.

Step 2: Evaluate PAP Therapy Adherence and Efficacy

Pulling Objective Compliance Data

Modern CPAP and APAP devices transmit nightly data to cloud portals (ResMed AirView, Philips DreamMapper). Pull at least the prior 90-day report and document:

• Average hours of use per night
• Percentage of nights meeting ≥4-hour threshold
• Residual AHI (or AHI on device, labelled "AHI" or "REI" depending on vendor)
• Mask leak percentile (95th-percentile leak should be <24 L/min for most masks)

The Medicare compliance definition of ≥4 hours on ≥70% of nights is a floor, not a ceiling. Patients with severe daytime sleepiness may need closer to 6-7 hours to resolve Epworth Sleepiness Scale scores. [2]

Residual AHI Targets

The treatment goal is a residual AHI <5 events/hour on therapy. A residual AHI of 5-9.9 warrants pressure adjustment or mask re-fitting. A residual AHI ≥10 despite optimal PAP settings should prompt re-referral to a sleep specialist to rule out central apnea, positional OSA, or equipment failure. [2]

Addressing Non-Adherence

Non-adherence is the single largest driver of treatment failure. In a meta-analysis of 22 randomized controlled trials published in JAMA Internal Medicine, motivational enhancement interventions increased CPAP use by a mean of 1.06 hours/night (95% CI 0.67-1.44). [7] Practical annual-visit strategies include:

• Switching mask interface (nasal pillow vs. Full-face vs. Nasal cushion)
• Initiating or renewing a heated humidifier
• Reviewing mouth-breathing with a chin strap trial
• Short-term CBT-I if insomnia is compounding adherence

Step 3: Weight and Body Composition Assessment

Why Weight Is a Core OSA Variable

Each 10% increase in body weight roughly doubles the odds of developing moderate-to-severe OSA, and weight loss of 10-15% can produce clinically meaningful AHI reductions. [8] The annual visit must include current BMI and ideally waist circumference (goal <40 inches in men, <35 inches in women per American Heart Association thresholds). [9]

GLP-1 and GIP/GLP-1 Agonists for OSA

In January 2024, the FDA approved tirzepatide (Zepbound) specifically for moderate-to-severe OSA in adults with obesity, the first pharmacologic approval for OSA itself. [10] This approval was based on the SURMOUNT-OSA trial (two cohorts, N=469 total).

In cohort 1 (patients not using PAP therapy), tirzepatide 10-15 mg weekly reduced AHI by 27.4 events/hour vs. 4.8 events/hour for placebo at 52 weeks. In cohort 2 (patients continuing PAP therapy), AHI fell by 30.4 events/hour vs. 6.0 events/hour for placebo. [11] Body weight fell by approximately 18-20% in the tirzepatide arms.

At the annual visit, clinicians should apply the following decision framework for GLP-1/GIP agonist candidacy in OSA:

1. BMI ≥30 (or ≥27 with a weight-related comorbidity) confirmed.
2. OSA severity moderate or severe on most recent objective study.
3. No personal or family history of medullary thyroid carcinoma or MEN2.
4. Patient willing to combine with dietary and activity modification.
5. Prior-authorization pathway documented if prescribing Zepbound for OSA indication.

Semaglutide (Ozempic, Wegovy) does not yet carry an FDA OSA indication, though the SCALE Sleep Apnea trial data showed liraglutide 3.0 mg reduced AHI by 12.2 events/hour vs. 6.1 for placebo over 32 weeks in patients with obesity. [12]

Documenting Weight Trajectory

Record current weight, 12-month weight change in absolute kilograms and percentage, and whether the patient is on a pharmacologic or surgical weight-loss program. Bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy) produces AHI reductions exceeding 60% in most series, though OSA may persist in up to 30% of patients post-operatively due to anatomical factors independent of fat distribution. [13]

Step 4: Cardiovascular and Metabolic Comorbidity Screening

Hypertension

OSA is present in approximately 50% of patients with resistant hypertension. [3] Check blood pressure at the annual visit and compare to prior readings. Patients with OSA and persistent hypertension despite two or more antihypertensives warrant re-evaluation of PAP adherence before adding a third agent. The JNC/ACC/AHA 2017 guidelines support this approach, noting that secondary causes of hypertension, including OSA, should be excluded or optimized before escalating pharmacotherapy. [9]

Atrial Fibrillation and Arrhythmia

OSA increases the risk of atrial fibrillation by 2-4 times and is independently associated with stroke. [14] At the annual visit, ask specifically about palpitations and new-onset irregular rhythm. A 12-lead ECG is reasonable in patients with moderate-to-severe OSA who report palpitations. Referral to cardiology is warranted if AF is identified, because cardioversion and ablation outcomes are significantly worse in untreated OSA. [14]

Metabolic Panel

The annual lab panel should include:

• Fasting glucose or HbA1c (OSA is independently associated with insulin resistance)
• Fasting lipid panel
• TSH (hypothyroidism can exacerbate OSA via upper-airway myxedema and central effects)
• CBC (secondary erythrocytosis may reflect chronic nocturnal hypoxia)

A 2016 meta-analysis in Diabetes Care (N=8,678 across 19 studies) found that OSA was associated with a 1.63-fold increased risk of type 2 diabetes independent of BMI. [15]

Step 5: Sleepiness and Quality-of-Life Reassessment

Epworth Sleepiness Scale

Administer the Epworth Sleepiness Scale (ESS) at every annual visit. A score of 0-10 is normal; 11-24 indicates pathologic sleepiness. Residual sleepiness (ESS ≥11) despite objective CPAP adherence and residual AHI <5 may indicate narcolepsy, idiopathic hypersomnia, or sleep-insufficient syndrome requiring additional workup. The FDA-approved wake-promoting agents solriamfetol (Sunosi) and modafinil (Provigil) are indicated for adjunctive treatment of residual sleepiness in adequately treated OSA. [16]

PROMIS Global Sleep Disturbance

Many practices now add the PROMIS Sleep Disturbance short form (4 or 8 items) alongside the ESS for a more granular quality-of-life snapshot. Both tools take under two minutes to complete and generate trackable longitudinal scores.

Driving Safety Documentation

Document explicitly in the annual note whether the patient is able to safely operate a vehicle. Patients with ESS ≥16 or any history of a drowsy-driving accident should be counseled against driving and referred urgently for therapy optimization. This documentation protects the clinician and meets medicolegal standards in most U.S. Jurisdictions. [5]

Step 6: Review Alternative and Adjunct Therapies

Mandibular Advancement Devices

Mandibular advancement devices (MADs) are guideline-recommended for patients with mild-to-moderate OSA who cannot tolerate PAP, and for severe OSA as an alternative when PAP adherence has repeatedly failed. [2] At the annual visit, ask CPAP users whether they have ever tried or would prefer a dental device. Efficacy is lower than CPAP on average but adherence is frequently higher, and the net therapeutic benefit may favor the MAD in low-severity cases. A 2015 JAMA trial (N=126) found no significant difference in blood pressure reduction between CPAP and MAD over 4 weeks. [17]

Positional Therapy

Approximately 56% of OSA patients have positional OSA, defined as AHI ≥2 times higher in the supine position. [18] Positional devices (vibrotactile trainers, commercially available anti-supine vests) reduce supine sleep time and may halve AHI in appropriate candidates without any airway device. Ask about sleep position at every annual visit.

Hypoglossal Nerve Stimulation

Upper airway stimulation (UAS) with the Inspire device is FDA-approved for adults with moderate-to-severe OSA (AHI 15-65) who have failed PAP therapy, have a BMI <40, and lack complete concentric collapse at the velum on drug-induced sleep endoscopy (DISE). The STAR trial (N=126) showed a 68% responder rate at 12 months, with a median 78% AHI reduction. [19] Refer to ENT or sleep surgery if the patient meets criteria.

Surgical Options

Uvulopalatopharyngoplasty (UPPP) remains the most common OSA surgery but produces highly variable outcomes. Maxillomandibular advancement (MMA) carries the strongest evidence in surgical series, with cure rates (AHI <5) approaching 40-50% in selected patients. [20] Surgical referral belongs in the annual conversation for any patient with long-standing PAP intolerance.

Step 7: Pediatric and Special Population Flags

Pregnancy

OSA in pregnancy is associated with gestational hypertension, preeclampsia, and fetal growth restriction. The AASM recommends screening all pregnant women with new-onset snoring, witnessed apneas, or obesity. CPAP is the treatment of choice; MADs are not recommended in pregnancy. [21] Any pregnant patient with OSA should be evaluated each trimester, not just annually.

Older Adults

AHI thresholds may require age-specific interpretation. Older adults show higher baseline AHI without equivalent cardiovascular risk, though recent data suggest the relationship is not benign. The American Geriatrics Society recommends maintaining OSA treatment in adults over 65 because of contributions to cognitive decline and fall risk. [22]

Step 8: Documentation, Coding, and Follow-Up Plan

ICD-10 and CPT Coding

• G47.33: Obstructive sleep apnea (adult)
• Z79.899: Long-term use of other medication (for PAP or pharmacologic therapy)
• CPT 95810: Polysomnography with CPAP titration, technician attended
• CPT 99213-99215: Established patient office visit (level by medical decision-making)

Annual Evaluation Note Must-Haves

Every annual OSA note should explicitly document:

1. Current AHI (from device data or most recent study)
2. PAP adherence percentage and hours per night
3. Current body weight and 12-month change
4. ESS score
5. Blood pressure reading
6. Lab results reviewed (glucose, HbA1c, lipid panel, TSH, CBC)
7. Comorbidities and any new diagnoses
8. Therapy changes made or planned
9. Driving safety counseling provided
10. Follow-up interval (typically 12 months unless changes require sooner review)

When to Shorten the Interval

Return in 3-6 months rather than 12 months if:

• Residual AHI ≥10 on current therapy
• New cardiovascular event in the interval
• Weight change exceeding 10% in either direction
• Starting tirzepatide, semaglutide, or bariatric surgery pathway
• Pregnancy confirmed or planned

Summary of the Annual OSA Checklist

| Domain | Key Action | Target / Pass Threshold | |---|---|---| | Diagnosis confirmation | Review original PSG/HSAT report | AHI ≥5 with symptoms or ≥15 any | | PAP adherence | Pull 90-day device report | ≥4 hr/night on ≥70% nights | | Residual AHI | Read device residual AHI | <5 events/hour | | Body weight | Measure weight and BMI | Document trajectory; flag ≥10% change | | GLP-1 candidacy | Screen BMI ≥30 with moderate/severe OSA | Refer or prescribe if criteria met | | Blood pressure | Clinic measurement | Target <130/80 mmHg (ACC/AHA) | | HbA1c or fasting glucose | Lab order or review | HbA1c <5.7% (normal range) | | Lipid panel | Lab order or review | LDL target per CV risk tier | | TSH | Lab order or review | 0.4-4.0 mIU/L | | ESS | Administer in office | Score 0-10 normal | | Driving safety | Document in note | Explicit counseling recorded | | Alternative therapy review | Ask about MAD, positional, UAS | Offer if PAP-intolerant | | Follow-up interval | Set next appointment | 12 months; 3-6 months if unstable |